Literature DB >> 34994387

IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation.

Armin Mortazavi1, Islam Fayed2, Muzna Bachani3, Tyrone Dowdy4, Jahandar Jahanipour5, Anas Khan1, Jemima Owotade1, Stuart Walbridge1, Sara K Inati1, Joseph Steiner3, Jing Wu4, Mark Gilbert4, Chun Zhang Yang4, Mioara Larion4, Dragan Maric5, Alexander Ksendzovsky6, Kareem A Zaghloul1.   

Abstract

BACKGROUND: Uncontrolled seizures in patients with gliomas have a significant impact on quality of life and morbidity, yet the mechanisms through which these tumors cause seizures remain unknown. Here, we hypothesize that the active metabolite d-2-hydroxyglutarate (d-2-HG) produced by the IDH-mutant enzyme leads to metabolic disruptions in surrounding cortical neurons that consequently promote seizures.
METHODS: We use a complementary study of in vitro neuron-glial cultures and electrographically sorted human cortical tissue from patients with IDH-mutant gliomas to test this hypothesis. We utilize micro-electrode arrays for in vitro electrophysiological studies in combination with pharmacological manipulations and biochemical studies to better elucidate the impact of d-2-HG on cortical metabolism and neuronal spiking activity.
RESULTS: We demonstrate that d-2-HG leads to increased neuronal spiking activity and promotes a distinct metabolic profile in surrounding neurons, evidenced by distinct metabolomic shifts and increased LDHA expression, as well as upregulation of mTOR signaling. The increases in neuronal activity are induced by mTOR activation and reversed with mTOR inhibition.
CONCLUSION: Together, our data suggest that metabolic disruptions in the surrounding cortex due to d-2-HG may be a driving event for epileptogenesis in patients with IDH-mutant gliomas. Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2022.

Entities:  

Keywords:  D-2-HG; IDH-mutated gliomas; Tumor-related epilepsy; mTOR

Mesh:

Substances:

Year:  2022        PMID: 34994387      PMCID: PMC9435503          DOI: 10.1093/neuonc/noac003

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  49 in total

1.  Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.

Authors:  Michael Wahl; Susan M Chang; Joanna J Phillips; Annette M Molinaro; Joseph F Costello; Tali Mazor; Sanda Alexandrescu; Janine M Lupo; Sarah J Nelson; Mitchel Berger; Michael Prados; Jennie W Taylor; Nicholas Butowski; Jennifer L Clarke; Daphne Haas-Kogan
Journal:  Cancer       Date:  2017-07-31       Impact factor: 6.860

2.  Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.

Authors:  Changho Choi; Jack M Raisanen; Sandeep K Ganji; Song Zhang; Sarah S McNeil; Zhongxu An; Akshay Madan; Kimmo J Hatanpaa; Vamsidhara Vemireddy; Christie A Sheppard; Dwight Oliver; Keith M Hulsey; Vivek Tiwari; Tomoyuki Mashimo; James Battiste; Samuel Barnett; Christopher J Madden; Toral R Patel; Edward Pan; Craig R Malloy; Bruce E Mickey; Robert M Bachoo; Elizabeth A Maher
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

3.  Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Authors:  Lukas Bunse; Stefan Pusch; Theresa Bunse; Felix Sahm; Khwab Sanghvi; Mirco Friedrich; Dalia Alansary; Jana K Sonner; Edward Green; Katrin Deumelandt; Michael Kilian; Cyril Neftel; Stefanie Uhlig; Tobias Kessler; Anna von Landenberg; Anna S Berghoff; Kelly Marsh; Mya Steadman; Dongwei Zhu; Brandon Nicolay; Benedikt Wiestler; Michael O Breckwoldt; Ruslan Al-Ali; Simone Karcher-Bausch; Matthias Bozza; Iris Oezen; Magdalena Kramer; Jochen Meyer; Antje Habel; Jessica Eisel; Gernot Poschet; Michael Weller; Matthias Preusser; Minou Nadji-Ohl; Niklas Thon; Michael C Burger; Patrick N Harter; Miriam Ratliff; Richard Harbottle; Axel Benner; Daniel Schrimpf; Jürgen Okun; Christel Herold-Mende; Sevin Turcan; Stefan Kaulfuss; Holger Hess-Stumpp; Karen Bieback; Daniel P Cahill; Karl H Plate; Daniel Hänggi; Marion Dorsch; Mario L Suvà; Barbara A Niemeyer; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nat Med       Date:  2018-07-09       Impact factor: 53.440

Review 4.  Neuronal activity in the glioma microenvironment.

Authors:  Tessa Johung; Michelle Monje
Journal:  Curr Opin Neurobiol       Date:  2017-11-06       Impact factor: 6.627

5.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

Review 6.  Nutrient sensing, metabolism, and cell growth control.

Authors:  Hai-Xin Yuan; Yue Xiong; Kun-Liang Guan
Journal:  Mol Cell       Date:  2013-02-07       Impact factor: 17.970

7.  TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice.

Authors:  Elisabeth Abs; Susanna M I Goorden; Jadwiga Schreiber; Iris E Overwater; Marianne Hoogeveen-Westerveld; Caroline F Bruinsma; Elvedin Aganović; Nils Z Borgesius; Mark Nellist; Ype Elgersma
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422

8.  NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria.

Authors:  Stefan Kölker; Verena Pawlak; Barbara Ahlemeyer; Jürgen G Okun; Friederike Hörster; Ertan Mayatepek; Josef Krieglstein; Georg F Hoffmann; Georg Köhr
Journal:  Eur J Neurosci       Date:  2002-07       Impact factor: 3.386

9.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

Review 10.  IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.

Authors:  Hui Yang; Dan Ye; Kun-Liang Guan; Yue Xiong
Journal:  Clin Cancer Res       Date:  2012-10-15       Impact factor: 13.801

View more
  1 in total

1.  Understanding epilepsy in IDH-mutated gliomas: towards a targeted therapy.

Authors:  Frank Winkler
Journal:  Neuro Oncol       Date:  2022-09-01       Impact factor: 13.029

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.